Table 5.
Frequency distribution of the number of patients with none or at least one sequencing mutation in KRAS, SMAD4, CDKN2A/P16 or TP53. (NS= non-smoker, S= smoker)
| Discovery Screen | Validation Screen | Combined Samples | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-smokers | Smokers | P | Non-smokers | Smokers | P | Non-smokers | Smokers | P | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | ||||
| KRAS | |||||||||||||||
| Wild-type | 0 | (0) | 0 | (0) | - | 0 | (0) | 1 | (2) | - | 0 | (0) | 1 | (2) | 1.00 |
| Mutated | 13 | (100) | 11 | (100) | 37 | (100) | 52 | (98) | 50 | (100) | 63 | (98) | |||
| SMAD4 | |||||||||||||||
| Wild-type | 8 | (62) | 8 | (73) | 0.68 | 28 | (76) | 39 | (74) | 1.00 | 36 | (72) | 47 | (73) | 1.00 |
| Mutated | 5 | (38) | 3 | (27) | 9 | (24) | 14 | (26) | 14 | (28) | 17 | (27) | |||
| CDKN2A/p16 | |||||||||||||||
| Wild-type | 12 | (92) | 10 | (91) | 1.00 | 30 | (81) | 38 | (72) | 0.33 | 42 | (84) | 48 | (75) | 0.26 |
| Mutated | 1 | (8) | 1 | (9) | 7 | (19) | 15 | (28) | 8 | (16) | 16 | (25) | |||
| TP53 | |||||||||||||||
| Wild-type | 2 | (15) | 4 | (36) | 0.36 | 4 | (11) | 10 | (19) | 0.38 | 6 | (12) | 14 | (22) | 0.22 |
| Mutated | 11 | (85) | 7 | (64) | 33 | (89) | 43 | (81) | 44 | (88) | 50 | (78) | |||